Industry Outlook

Anti-inflammatory therapeutics market expected to reach by US$ 186.1 Bn by 2030 with CAGR of 8.5% during the forecast period from 2023 to 2030. Biologics and immune selective anti-inflammatory derivatives (ImSAIDs) are the promising drugs classes playing major role in the market. North America clearly holds major share in the global anti-inflammatory therapeutics market, as the key companies headquartered in the region. Non-steroidal anti-inflammatory drugs are used for the treatment of chronic and acute pain. Either its headache or migraines, ligament sprain, menstrual pain, and rheumatoid arthritis, anti-inflammatory drugs can treat faster as compared to other drugs. They are equipped for bringing down the level of prostaglandins, the chemicals are responsible for reducing pain, swelling, and inflammation.

Rising incidence of respiratory and autoimmune diseases, expanding investments in Asia-Pacific and Europe and a substantial number of biologics in the expansion pipeline will drive the development of global anti-inflammatory therapeutics market. Factors such as, the presence of recognized markets for biologics and corticosteroids, larger acceptance of OTC NSAIDs, for example, naproxen and ibuprofen, in countries like Indian and China would additionally enhance the market growth in Asia Pacific region.

The United States is leading market in North America at the global level, and Japan is the foremost market for biologic drugs in Asia Pacific market. While United Kingdom is projected to lead the market in Europe. Moreover, in Japan, the administration is currently focusing on the establishment of viable generic drugs. Furthermore, China anticipated to rise as the new market front-runner in Asia Pacific market by 2026 owing to rapidly developing economy, developing healthcare facilities and immense patient base. In India, the introduction of biosimilars and continuously improving healthcare expenses will be the main variables encouraging the development of anti-inflammatory therapeutics market.

"Corticosteroids drugs boosting the growth of anti-inflammatory therapeutics market"

Currently, corticosteroids are the largest drug type by value and estimated to retain its prominence and biologics to record highest double-digit CAGR throughout the forecast period from 2023-2030. According to WHO the prevalence of rheumatoid arthritis contrasts between 0.3% and 1% which is more typical in women. About 1.5 million people in the United States have rheumatoid arthritis (RA). Corticosteroids are used to treat systemic lupus, severe psoriasis and to suppress the immune system.

"IBD segment by indication to record highest double digit CAGR during the forecast period"

According to CDC (Centers for Disease Control and Prevention), in the US, it is presently projected that around 1 Mn to1.3 Mn people affected by IBD. Moreover, studies from various nations exhibit that the incidence of IBD is growing, particularly in adolescence. Right now, the most elevated yearly incidence of IBD (Inflammatory bowel disease) in Europe was 12.7 for every 100,000 person-years for CD (Crohn’s Disease) and 24.3 for every 100,000 person-years for UC (Ulcerative Colitis). In North America, the yearly incidence of IBD was 19.2 for every 100,000 men a long time for UC and 20.2 for every 100,000 person-years for the CD. Whereas in Asia and the Middle East it was 6.3 for every 100,000 person-years for UC and 5.0 for every 100,000 person-years for the CD. The maximum prevalence for UC was 505 for every 100,000 people in Europe and 249 for every 100,000 people in North America. The yearly prevalence of CD was 322 for every 100,000 people in Europe and 319 for every 100,000 people in North America. So, it is expected that these factors will encourage the development of anti-inflammatory therapeutics market.

This detailed study further defines the major qualitative market assessment factors including main market driver, market trends and restraints, to help in better understanding of global anti-inflammatory therapeutics market. Each market valuation factor comprising challenges, market drivers and opportunities are widely elucidated considering the existing market scenario. This report graphically maps the market players based on their market initiatives and product offering, strategies and business strength. Moreover, the report provides attractive investment proposition based on the extensive geographical research. Key players profiled in the report include: AbbVie Inc., Amgen Inc., AstraZeneca plc, Eli Lily and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Company, Inc., Novartis International AG, Pfizer Inc., and F. Hoffmann-La Roche AG among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anti-Inflammatory Therapeutics market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Anti-Inflammatory Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Anti-Inflammatory Therapeutics market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Anti-Inflammatory Therapeutics market?
• Which is the largest regional market for Anti-Inflammatory Therapeutics market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Anti-Inflammatory Therapeutics market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Anti-Inflammatory Therapeutics market worldwide?